Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban vs Rivaroxaban in Acute Pulmonary Embolism
NCT07774273Completed
- Sponsor
- Combined Military Hospital Lahore
- Start
- Jan 2021
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Randomised, open-label trial of apixaban in pulmonary embolism (PE) (2 arms), sponsored by Combined Military Hospital Lahore. Primary endpoint: Composite of major bleeding or clinically relevant non-major (CRNM) bleeding at 3 months. Started Jan 2021; status: completed.
02
Drugs
apixaban
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT07774273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07774273.